AI Multi-Horizon Analysis
No intraday technical data available. Price anchored at $423 near recent insider sales; near-term direction undecided pending market open and sentiment.
Positive margin and revenue trends support stability, but insider selling and valuation concerns limit upside conviction in the days-to-weeks horizon.
Recurring revenue model, installed-base growth, margin expansion, debt-free balance sheet and strong cash flow support long-term outperformance, tempered by valuation and competitive risks.
Strong fundamental momentum with accelerating revenue, expanding margins, zero debt and robust liquidity is offset by routine but sizable insider net selling and a premium valuation. Technical context is limited; price near insider sale levels.
Detailed AI Fundamental Analysis
Business Snapshot
Intuitive Surgical Inc. (ISRG) designs, manufactures, and markets the da Vinci surgical robotic system and related instruments and accessories used in minimally invasive procedures. The company operates in the orthopedic, prosthetic, and surgical appliances & supplies industry, generating revenue primarily through system placements, recurring instrument and accessory sales, and service contracts. With approximately 17,021 employees and 353.9 million shares outstanding, ISRG commands a market capitalization of roughly $150.7 billion at the current price of $423.00 per share. The business model is heavily weighted toward high-margin recurring revenue from consumables tied to installed base utilization.
Financial Trends
Revenue has shown consistent acceleration across the last four reported quarters. Quarterly revenue rose from $2.505 billion in 2025-09-30 to $2.770 billion in 2026-03-31 (+10.6% QoQ) and further to $2.892 billion in 2026-06-30 (+4.4% QoQ). On a trailing basis, the latest quarter represents a 15.5% increase versus the same period four quarters prior.
Gross margin has expanded steadily, improving from 66.36% in 2025-09-30 to 66.78% in 2026-06-30. Operating margin exhibited the strongest upward trajectory, climbing from 30.33% to 33.60% over the same span, with a notable acceleration in the most recent quarter (+2.73 percentage points QoQ). Net margin has been relatively stable, fluctuating between 28.12% and 29.65%, ending at 28.29% in 2026-06-30.
Balance-sheet strength continued to improve. Total assets grew from $19.352 billion four periods ago to $20.877 billion in 2026-06-30 (+7.9%). Shareholders’ equity expanded from $16.930 billion to $18.168 billion (+7.3%). Cash & equivalents rose from $2.807 billion to $2.760 billion in the latest period after peaking at $3.368 billion at 2025-12-31. Inventory increased steadily from $1.782 billion to $2.029 billion (+13.9% over four periods), consistent with business growth.
Cash from operations demonstrated volatility but remains robust: $2.138 billion (2025-09-30), $3.031 billion (full-year 2025-12-31), $0.912 billion (2026-03-31), and $1.973 billion (2026-06-30). Financing cash flows have been consistently negative due to share repurchases, totaling approximately $7.6 billion in outflows across the four periods. Free Cash Flow line items are not provided in the data.
Financial Health
The most recent quarter (2026-06-30) reflects a healthy and improving financial position. Current ratio stands at a strong 4.96, up from 4.61 in the prior quarter, with working capital of $7.620 billion. The company carries no reported debt (Debt/Equity shown as —), resulting in an unlevered balance sheet with $18.168 billion in equity supporting $20.877 billion in total assets. Operating income reached a four-period high of $972 million, and net income of $818 million remains near peak levels despite minor QoQ variability.
The combination of expanding operating margins, accelerating revenue, robust liquidity, and zero debt provides ISRG with significant financial flexibility to invest in R&D, capacity expansion, and potential share repurchases. Retained earnings of $6.837 billion (down slightly from year-end due to buybacks) still reflect cumulative profitability. Overall, the latest period confirms a high-quality balance sheet with positive momentum in profitability metrics.
Insider Activity
Insider sentiment over the most recent reported window (2026-07-18 to 2026-10-16) is Neutral with a score of -10. While there were 4 buy transactions totaling $102,933, these were dwarfed by 26 sell transactions amounting to $5.980 million, resulting in net selling of $5.878 million.
Recent Form 4 filings show a pattern of executives exercising options (reflected as zero-cost buys) followed by immediate sales. On 2026-10-10, Patricia L. Wadors sold 1,062 shares at $423.96 for $450,246 and Gary Loeb sold 1,296 shares at the same price for $549,452. In September, Fredrik Widman executed option exercises and sold a combined 1,089 shares at $374.44. These sales occurred near or above recent price levels and are consistent with routine equity compensation monetization rather than outright bearish conviction. Net selling activity is notable in absolute terms but typical for a growth-oriented technology/medical device company with significant insider ownership and equity-based compensation.
Multi-Timeframe Technical Context
With the market closed and the active timeframe marked as fundamental, price action is anchored at $423.00. The absence of intraday (1m–15m), hourly, or daily candle and indicator data limits real-time technical interpretation. On a longer-horizon basis, the current price sits within the range of recent insider sales executed between approximately $374 and $424, suggesting the stock is trading near levels where insiders have been willing to monetize equity. Without explicit moving averages, RSI, volume profiles, or multi-timeframe trend indicators, technical context is constrained to the fundamental price reference of $423.00 and the observed insider transaction prices.
Bull / Bear Cases
Short-term (hours to days):
Bull case: Continued positive momentum from the latest quarter’s margin expansion and revenue beat could support a retest of recent highs if post-earnings sentiment remains constructive. Strong liquidity and zero debt provide a safety net against near-term volatility.
Bear case: Persistent net insider selling and any negative reaction to the minor QoQ dip in net income could trigger short-term profit-taking, especially if broader market sentiment sours. Price action near $424 (recent sale level) may act as immediate resistance.
Long-term (weeks to months):
Bull case: Sustained acceleration in revenue, expanding operating margins (now at 33.6%), growing installed base, and recurring revenue model should continue to drive earnings power. Debt-free balance sheet and robust cash generation provide runway for innovation and market share gains in robotic surgery.
Bear case: If margin gains plateau or inventory growth outpaces utilization trends, investors may question the durability of the growth trajectory. Regulatory or competitive pressures in the surgical robotics space could slow adoption, pressuring the premium valuation implied by the $150.7 billion market cap.
Key Levels & Triggers
- Immediate Support: $374 (recent insider sale cluster level observed in September transactions).
- Near-term Resistance: $424 (exact price at which multiple October insider sales were executed).
- Fundamental Trigger (Bullish): Quarterly revenue exceeding $2.9 billion combined with operating margin holding above 33% and continued cash flow strength.
- Fundamental Trigger (Bearish): Deceleration in gross or operating margin, unexpected slowdown in system placements, or acceleration in inventory relative to revenue.
- Valuation / Capital Return Trigger: Further share repurchases funded by the $1.97 billion quarterly operating cash flow could act as a positive catalyst given the reduction in shares outstanding from 361.8 million (diluted, four periods ago) to 357.3 million latest.
- Liquidity Milestone: Sustained cash & equivalents above $2.5 billion with current ratio > 4.5 remains a key health indicator supporting long-term conviction.